Novartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, the first biosimilar cleared by the FDA. Zarxio (filgrastim-sndz) is a biosimilar ...

No details about pricing have been released by Sandoz yet, though it priced its first US biosimilar Zarxio at 15% discount to the originator drug Neupogen, another Amgen drug. Sandoz gave no ...

when the FDA approved Novartis subsidiary Sandoz's application to sell Zarxio, a biosimilar of Amgen's Neupogen, which stimulates white blood cell production. Health plan sponsors are eager for ...

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of ...

ZURICH, April 14 (Reuters) - Swiss generic drug manufacturer Sandoz (SDZ.S), opens new tab said on Monday it had filed an antitrust lawsuit in the United States against Amgen (AMGN.O), opens new ...

Sandoz has filed an antitrust lawsuit in the United States against Amgen, for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel (etanercept). The drug was ...

Sandoz has filed an antitrust lawsuit in the US against Amgen, challenging alleged anti-competitive practices surrounding the biologic blockbuster Enbrel (etanercept). Filed at the US District ...

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of its ...

Hoping to alter the timetable is Swiss generics and biosimilars specialist Sandoz, which has filed an antitrust lawsuit in federal court in Virginia claiming that Amgen has blocked competition to ...

Etanercept is a biologic medicine used to treat various inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Basel, April 14, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced ...